Thus, in the present study, we describe the synthesis of CHX-A''-DTPA-DUPA-Pep (Scheme 1), subsequent labelling with Ga-68, Y-90 and Lu-177, and the investigation of its biological activity as a new potential PSMA ligand for the diagnosis and therapy of prostate cancer. Here, FOLH1 is linked to prostate carcinoma.